In prostate cancer, HDAC6 expression levels was not associated with disease outcomes [18], while increased HDAC6 expression was shown to be associated with a more advanced stage in oral squamous cancers [16] and a poorer prognosis in high grade gliomas [19]. Here, HDAC6 is linked to glioma.